Barchart Demo Center

Overview

Stocks

Stock Screeners

ETFs

Futures

Funds

Fund Screeners

Foreign Exchange

Sectors

News

Financial Calculators

Embedded Widgets

Portfolio

Screener

JSON Feeds

Symbol Overview

United States|Canada
English|French

Immuron Ltd

(NASDAQ: IMRN)
Add to Portfolio
+0.01 (+0.36%)
as of Sep 20, 2019

Last 2.76
Change +0.01 (+0.36%)
Open 2.80
Prev. Close 2.75
Today's Range
2.75
2.80
52wk Range
2.23
10.11
Volume 4,500
Avg Volume 12,600
Sector SIC-2834 Pharmaceutical Preparations

Perfomance Comparison

Name Today 3-Month 1-Year
IMRN +0.36% -4.83% -71.25%
DJIA -0.59% -0.56% +1.04%
S&P 500 -0.49% -0.26% +2.09%

Key Statistics

Annual EPS N/A
Dividend Yield 0.00%
P/E Ratio N/A
Market Capitalization, $K 10,170
Weighted Alpha -72.60
Standard Deviation +0.10
Profit Margin N/A
Beta 2.44

Growth Rates

YTD -52.41%
1-Year -71.98%

Opinion

Sell Hold Buy

Recent Headlines

U.S. Defense Reports Immuron's Travelan(R)

GlobeNewswire via COMTEX - Wed Sep 04, 07:14AM EDT
Key Highlights:(full story)
IMRN: 2.76 (+0.01)

Immuron to Commence Non-Deal Investor Roadshow

GlobeNewswire via COMTEX - Fri Aug 16, 06:00AM EDT
Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian biopharmaceutical company focused on developing and commercializing oral immunoglobulin therapeutics for the treatment of gut mediated diseases, today is pleased to release t(full story)
IMRN: 2.76 (+0.01)

BriaCell Appoints Richard J. Berman to Board of

GlobeNewswire via COMTEX - Mon Aug 12, 06:30AM EDT
BriaCell Therapeutics Corp. ("BriaCell" or the "Company") (TSX-V:BCT) (OTCQB:BCTXF), a clinical-stage biotechnology company specializing in targeted immunotherapy for advanced breast cancer, today announced that it has appointed M(full story)
BCTXF: 0.0550 (-0.0074), ADXS: 0.29 (-0.01), IMRN: 2.76 (+0.01), CATS: 17.69 (+0.67), CYRX: 17.66 (-0.11), BCT.VN: 0.065 (-0.015), BIVI: 0.0750 (unch)

Immuron Reports Results in Severe Alcoholic Hepatitis

GlobeNewswire via COMTEX - Thu Aug 08, 12:00PM EDT
Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian biopharmaceutical company focused on developing and commercializing oral immunotherapeutics for the treatment of gut mediated diseases, today announced the topline results of(full story)
IMRN: 2.76 (+0.01)

Immuron to Host Investor Webinar on July 18 to Provide

GlobeNewswire via COMTEX - Wed Jul 17, 06:00AM EDT
Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian biopharmaceutical company, announced today that it will participate in an investor webinar and Q&A session on Thursday, July 18, 2019, at 10:30 a.m. EST (US time), hosted by (full story)
IMRN: 2.76 (+0.01)